Shock: A Challenger Challenged; Emergency Med.5: 95–103 (Mar.) 1973.
4.
SchumerW., Dexamethasone In Oligemic Shock, Arch. Surg.98: 259–261 (Mar.) 1969.
5.
WilsonJ.W., Treatment or Prevention of Pulmonary Cellular Damage With Pharmacologic Doses of Corticosteroid, Surg. Gynecol. Obstet.134: 675–681 (Apr.) 1972.
6.
LindenbaumJ.: Variation in Biologic Availability of Digoxin From Four Preparations, N. E. J. Med.285: 1344–1347, 1971.
7.
ManninenV., MelinJ., and HartelG.: Serum-Digoxin Concentrations During Treatment With Different Preparations, Lancet2: 934–935, 1971.
8.
ShawT.R.D., HowardM.R., and HamerJ.: Variation in the Biological Availability of Digoxin, Lancet2: 303–307, 1972.
9.
BinnionP.F., and McDermottM.: Bioavailability of Digoxin, Lancet2: 592, 1972.
10.
BertlerA.: Bioavailability of Digoxin. Lancet2: 708, 1972.
11.
LindenbaumJ.: Variation in Digoxin Bioavailability: A Continuing Problem, J. Chron. Dis., In Press.
12.
HamerJ., and Grahame-SmithD.G.: Bioavailability of Digoxin, Lancet2: 325, 1972.
13.
StewartM.J., and SimpsonE.: New Formulation of Lanoxin: Expected Plasma Levels of Digoxin, Lancet2: 541, 1972.
14.
WhitingB., RodgerJ.C., and SummerD.J.: New Formulation of Digoxin, Lancet2: 922, 1972.
15.
ManninenV., OjalaK., and ReissellP.: New Formulation of Digoxin. Lancet2: 922–923, 1972.
16.
StollR.G.: The Bioavailability of Two Commercial Digitoxin Tablets Using the Radioimmunoassay, J. Pharm. Sci., Submitted.
